 announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co., Ltd. The Japanese pioneer in biotherapeutics is leveraging the 

 to support research on a therapy for the treatment of Fabry disease. With a primary focus on biotherapeutics that use recombinant DNA (rDNA) technology to address significant unmet medical needs, JCR Pharmaceuticals is developing therapeutic enzymes to treat lysosomal storage diseases (including Fabry disease), a group of rare genetic diseases that occur in very small patient populations.  For its clinical study on a Fabry disease treatment, JCR Pharmaceuticals has selected Medidata’s cloud-based technology for electronic data capture and management (

News

Medidata announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co., Ltd.